Truist Securities downgrades Alnylam Pharmaceuticals to Hold from Buy, lowers price target to $225 from $315
Truist Securities downgraded Alnylam Pharmaceuticals to Hold from Buy, reducing its price target to $225 from $315. This implies a 52.9% upside from the Oct 30 close of $147.17. Recent analyst price targets for the company range from $199 to $354.
How this was made
The 30-second read
Why it matters
This is an analyst-driven sentiment reset for ALNY, with a notably lower target and a downgrade from Buy to Hold, which can influence positioning and near-term trading flows.
Market read
Traders may adjust short-term expectations for ALNY based on the downgrade and the magnitude of the target cut, while monitoring whether other analysts converge.
What to watch
The article does not cite a specific new thesis or catalyst behind the downgrade, so traders should watch for follow-up notes that explain the driver (pipeline, competition, trial risk, or valuation).
Background
The piece summarizes a Truist Securities rating change for Alnylam and notes the spread of recent analyst price targets over the prior month.
Ticker impact
Truist downgraded Alnylam Pharmaceuticals to Hold from Buy and cut its price target to $225 from $315, signaling reduced upside expectations.
Likely downward pressure as the market reprices the stock’s expected risk-reward based on the lowered target and rating.
The article provides a clear rating change (Buy to Hold) and a substantial target reduction, which typically weighs on momentum even without new company fundamentals.
Market effects
Could modestly dampen sentiment for RNAi/biopharma peers if investors generalize from the downgrade to the group’s near-term outlook.
Limited, since this is a single-name analyst action rather than a broad macro or sector catalyst.
Low, as the event is US-focused analyst commentary on a single company.
Counterpoint
The downgrade may be more about valuation or expectations than a new fundamental deterioration; other analysts’ targets in the $199 to $354 range suggest disagreement remains.
Key entities
- companyAlnylam Pharmaceuticals
Subject of the downgrade, with Truist cutting its rating and price target.
- analyst_firmTruist Securities
Brokerage issuing the downgrade to Hold and lowering the price target.
